A large prospective study showed that primary aldosteronism (PA) is the most prevalent form of endocrine hypertension among hypertensive patients referred to specialized hypertension centers. 1 The discrimination between its main subtypesaldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH, also referred to as idiopathic hyperaldosteronism, IHA)-is crucial, as the former is surgically curable, whereas the latter requires lifelong medical treatment.2,3 This distinction is, however, challenging because of the biochemical and pathological overlapping of APA and BAH, and the lack of well-defined functional and morphological criteria. The tissue surrounding the APA often contains multiple nodules and shows paradoxical hyperplastic changes. Furthermore, cases of multinodular adrenal hyperplasia have been reported, 4 even though their distinctive criteria from APA remain vague.Thus, a pathological continuum between APA and BAH featuring a transition from hyperplasia to a nodular phase has been proposed, 5 which suggests that pathogenic mechanisms common to these conditions exist. However, the stimuli driving this transition eluded identification thus far notwithstanding a long quest. For example, even though angiotensin-II type-1 (AT1) receptors were detected in both the normal adrenocortical zona glomerulosa and in APA, 6-8 angiotensin-II (Ang-II), one of the known secretagogues of aldosterone, is barely detectable in PA patients.Of interest, circulating autoantibodies against a specific epitope of the AT1 receptor (AT1AA) with specific agonistic activity have been suggested to play a pathogenic role in diseases characterized by vascular and renal damage, such as preeclampsia and malignant hypertension.
9-16These agonistic autoantibodies against type-1 angiotensin-II receptor (AT1AA) could stimulate aldosterone secretion and trigger the development of hyperplastic changes in the zona glomerulosa in PA patients. We therefore sought for AT1AA in serum of patients with PA and investigated whether their titer was higher Abstract-The mechanisms of excess aldosterone secretion in primary aldosteronism (PA) remain poorly understood, although a role for circulating factors has been hypothesized for decades. Agonistic autoantibodies against type-1 angiotensin-II receptor (AT1AA) are detectable in malignant hypertension and preeclampsia and might play a role in PA. Moreover, if they were elevated in aldosterone-producing adenoma (APA) and not in idiopathic hyperaldosteronism (IHA), they might be useful for discriminating between these conditions. To test these hypotheses, we measured the titer of AT1AA in serum of 46 patients with PA (26 with APA, 20 with IHA), 62 with primary hypertension (PH), 13 preeclamptic women, and 45 healthy normotensive blood donors.We found that the AT1AA titer was higher (P<0.